BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,253,276 | -20.0% | 150,627 | -4.1% | 0.02% | -19.0% |
| Q2 2023 | $12,822,196 | +6.8% | 157,077 | -3.0% | 0.02% | +5.0% |
| Q1 2023 | $12,010,619 | -11.7% | 161,890 | -1.4% | 0.02% | -16.7% |
| Q4 2022 | $13,607,643 | +13.4% | 164,184 | +288.7% | 0.02% | -4.0% |
| Q3 2022 | $11,995,000 | -19.6% | 42,234 | -1.8% | 0.02% | -13.8% |
| Q2 2022 | $14,910,000 | -21.5% | 43,012 | -1.9% | 0.03% | -9.4% |
| Q1 2022 | $18,994,000 | -18.1% | 43,864 | -2.2% | 0.03% | -13.5% |
| Q4 2021 | $23,202,000 | +5.2% | 44,847 | -1.5% | 0.04% | -9.8% |
| Q3 2021 | $22,054,000 | +8.9% | 45,512 | +1.2% | 0.04% | +7.9% |
| Q2 2021 | $20,249,000 | +21.0% | 44,971 | +2.6% | 0.04% | +11.8% |
| Q1 2021 | $16,740,000 | +14.2% | 43,829 | -5.1% | 0.03% | +6.2% |
| Q4 2020 | $14,661,000 | +33.2% | 46,174 | +3.9% | 0.03% | +18.5% |
| Q3 2020 | $11,007,000 | -2.7% | 44,433 | +3.7% | 0.03% | -10.0% |
| Q2 2020 | $11,316,000 | +34.3% | 42,855 | -3.5% | 0.03% | +15.4% |
| Q1 2020 | $8,424,000 | -12.1% | 44,420 | +1.7% | 0.03% | +4.0% |
| Q4 2019 | $9,587,000 | +11.0% | 43,674 | -1.0% | 0.02% | +4.2% |
| Q3 2019 | $8,636,000 | -4.1% | 44,134 | +2.2% | 0.02% | -4.0% |
| Q2 2019 | $9,007,000 | +4.4% | 43,200 | -0.6% | 0.02% | 0.0% |
| Q1 2019 | $8,628,000 | +10.3% | 43,455 | -19.6% | 0.02% | 0.0% |
| Q4 2018 | $7,821,000 | -28.7% | 54,041 | +0.5% | 0.02% | -21.9% |
| Q3 2018 | $10,972,000 | +35.8% | 53,756 | -1.6% | 0.03% | +28.0% |
| Q2 2018 | $8,080,000 | -2.5% | 54,614 | -0.4% | 0.02% | 0.0% |
| Q1 2018 | $8,285,000 | +8.1% | 54,848 | -7.3% | 0.02% | +8.7% |
| Q4 2017 | $7,661,000 | +4.9% | 59,136 | -2.2% | 0.02% | 0.0% |
| Q3 2017 | $7,305,000 | +1.6% | 60,436 | -1.3% | 0.02% | -4.2% |
| Q2 2017 | $7,192,000 | +13.0% | 61,212 | -2.3% | 0.02% | +9.1% |
| Q1 2017 | $6,367,000 | -0.5% | 62,637 | +0.6% | 0.02% | -4.3% |
| Q4 2016 | $6,399,000 | -5.9% | 62,236 | +0.3% | 0.02% | -8.0% |
| Q3 2016 | $6,797,000 | -20.8% | 62,069 | -18.4% | 0.02% | -24.2% |
| Q2 2016 | $8,578,000 | +139.0% | 76,071 | +100.4% | 0.03% | +135.7% |
| Q1 2016 | $3,589,000 | +8.9% | 37,966 | +3.7% | 0.01% | +7.7% |
| Q4 2015 | $3,297,000 | -2.9% | 36,618 | -0.3% | 0.01% | -7.1% |
| Q3 2015 | $3,397,000 | +4.1% | 36,739 | +10.9% | 0.01% | +7.7% |
| Q2 2015 | $3,263,000 | -3.7% | 33,133 | -2.0% | 0.01% | 0.0% |
| Q1 2015 | $3,390,000 | +29.4% | 33,803 | +19.3% | 0.01% | +30.0% |
| Q4 2014 | $2,620,000 | – | 28,344 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |